DGAP-News: Xlife Sciences AG
/ Key word(s): Investment
18.03.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
Xlife Sciences AG (XLS): Joint venture with Indivumed
New perspectives for the fight against cancer
Xlife Sciences AG has entered into a joint venture with Hamburg based Indivumed GmbH. Ix Therapeutics GmbH, founded for this purpose, will use Indivumed’s extensive multi-omics database and analysis capacities in the future. Functional therapeutic antibodies are developed on this basis on the technology platform of Veraxa Biotech AG, an Xlife portfolio company. The collaboration opens up completely new possibilities for cancer treatment.
The IndivuType database developed by Indivumed is the world’s only combined collection of high-quality multi-omics and accompanying clinical data from thousands of cancer patients combined with whole genome sequencing, transcriptomics, proteomics, and phosphoproteomics data. Oliver R. Baumann, CEO of Xlife, sees the collaboration as a milestone for his company. “We are fascinated by IndivuType and its possibilities for recognizing possible disease triggers. This analytical ability in combination with Veraxa’s antibody development will open up new ways for us to treat various types of cancer in a short time frame,” says Baumann. Prof. Dr. Hartmut Juhl, CEO of Indivumed, sees huge potential in the joint venture. “With the partnership with Xlife and Veraxa Biotech AG as service providers, we are for the first time able to develop functional antibodies against cancer based on our database and analysis tools. This brings us a big step closer to our vision of a fully individualized cancer therapy”.
Initially, lx Therapeutics will concentrate on the treatment of colon and lung cancer. To this end, Indivumed will identify various new disease triggers in the future, which will be made available to lx Therapeutics exclusively for the development of functional therapeutic antibodies based on the Veraxa Biotech AG platform.
About Xlife Sciences AG
Information to media professionals:
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Frankfurt, Munich|
|EQS News ID:||1176442|
|End of News||DGAP News Service|